SlideShare a Scribd company logo
1 of 1
Weighted Average Blood Pressure as a Predictor of
Cardiovascular Disease
Ije Okafor, Anthony Bonifonte M.S., Dr. Turgay Ayer PhD
H . Milton Stewart School of Industrial & Systems Engineering, Georgia Institute of Technology, Atlanta, GA
• Cardiovascular disease (CVD) is America’s leading health problem, and the leading
cause of death worldwide
• High blood pressure, also known as hypertension, is the most important risk factor for
premature cardiovascular disease
• Traditional risk factors for CVD include age, sex, cholesterol, smoking, diabetes, and
elevated levels of BP
Background:
Previous Study:
Conclusions:
• Antecedent BP is a statistically significant predictor of CVD risk
• Antecedent BP is a stronger predictor of CVD risk than current BP
Study used the simple average of antecedent BP measurements
Research Objective: Study Inclusion:
Determine if weighted average antecedent
BP is a better predictor of CVD risk than
simple average antecedent BP
• Framingham Heart Study
• 3909 patients attended Baseline Exam 8
• 2127 patients met selection criteria
Core logistic regression models:
• Traditional risk factors + Current BP
• Traditional risk factors + Antecedent BP
• Traditional risk factors + Antecedent BP + Current BP
Clinical Measurements:
Current BP Model
HR (95% CI) & P
Value
Antecedent BP Model
HR (95% CI) & P Value
Current and Antecedent BP
Model
HR (95% CI) & P Value
Age 1.03 (1.02-1.04) <.001 1.03 (1.02-1.04) <.001 1.03 (1.02-1.04) <.001
Sex 1.75 (1.50-2.06) <.001 1.80 (1.52-2.10) <.001 1.79 (1.52-2.10) <.001
Smoking (yes/no) 1.31 (1.12-1.54) <.001 1.36 (1.16-1.60) <.001 1.35 (1.15-1.58) <.001
Diabetes (yes/no) 1.23 (1.04-1.47) .0186 1.24 (1.05-1.48) .0143 1.23 (1.03-1.47) .0195
Cholesterol
(10 mg/dL)
1.03 (1.01-1.05) .0019 1.03 (1.00-1.01) .0028 1.03 (1.01-1.05) .0033
Diuretics 1.80 (1.35-2.40) <.001 1.46 (1.11-2.02) .0117 1.54 (1.14-2.07) .0043
Current BP
(10 mm Hg)
1.23 (1.19-1.27) <.001 1.12 (1.06-1.18) <.001
Antecedent BP
(10 mm Hg)
1.28 (1.24-1.36) <.001 1.16 (1.09-1.24) <.001
Methodology: Exponential Smoothing
Assigns exponentially decreasing weights to older observations.
Standard Formula: Ft+1 = (λ)Dt + (1-λ) Ft
• Ft+1 = Final weighted observation
• Dt = Current observation
• Ft = Previous observation
• λ = A weighing factor referred to as the smoothing constant
0.70048
0.7005
0.70052
0.70054
0.70056
0.70058
0.7006
0.70062
0.28 0.285 0.29 0.295 0.3 0.305 0.31 0.315 0.32
C-Index
Smoothing Constant (λ )
Optimal Smoothing Constant
Results:
Weighted Average Model vs. Simple Average Model
Current BP + Weighted Antecedent BP
HR (95% CI) & P Value
Current and Antecedent BP Model
HR (95% CI) & P Value
Age 1.03 (1.02-1.04) <.001 1.03 (1.02-1.04) <.001
Sex 1.78 (1.51-2.09) <.001 1.79 (1.52-2.10) <.001
Smoking (y/n) 1.35 (1.15-1.58) <.001 1.35 (1.15-1.58) <.001
Diabetes (y/n) 1.23 (1.03-1.46) .0217 1.23 (1.03-1.47) .0195
Cholesterol
(mg/dL)
1.03 (1.01-1.05) .0039 1.03 (1.01-1.05) .0033
Diuretics 1.53 (1.14-2.05) .0051 1.54 (1.14-2.07) .0043
Current BP 1.11 (1.05-1.17) <.001 1.12 (1.06-1.18) <.001
Antecedent BP
(Simple Avg)
1.16 (1.09-1.24) <.001
Antecedent BP
(Weighted Avg)
1.17 (1.09-1.25) <.001
Conclusion:
• Using a weighted antecedent BP average over a simple average showed some
improvements; however, this data was not statistically significant
• Refinement to this study may bring statistically significant results
Study Limitations:
• Predominately white study population
• Older population; more cases of CVD
• Sensitive smoothing constant
Future Work:
• Conduct a similar study on a more diverse population
• Explore all possible smoothing constant values; apply to additional models
• Explore weighing options outside of exponential smoothing
Acknowledgements: References:
1. Bonifonte, Anthony, MS, Turgay Ayer, PhD, Emir Veledar, PhD, Allison
Clark, BA, and Peter W.F. Wilson, MD. "Antecedent Blood Pressure as a
Predictor of Cardiovascular Disease." Journal of American Society of
Hypertension (2015): 690-96. Web.
1. Vasan, Ramachandran S., Joseph M. Massaro, Peter W.F. Wilson, Sudha
Seshadri, Philip A. Wolf, Daniel Levy, and Ralph B. D'Agostino.
"Antecedent Blood Pressure and Risk of Cardiovascular Disease: The
Framingham Heart Study." Journal of the American Heart
Association(2001): 48-53. Web
2. Chen, Ruijun, Kumar Dharmarajan, Vivek T. Kulkarni, Natdanai
Punnanithinont, Aakriti Gupta, Behnood Bikdeli, Purav S. Mody, and
Isuru Ranasinghe. "Most Important Outcomes Research Papers on
Hypertension." Journal of the American Heart Association (2013): 26-35.
Web.
• Anthony Bonifonte, Graduate Advisor
• Dr. Turgay Ayer, Faculty Advisor
• SURE Program, Summer 2016
Results: C-Statistic
Traditional risk factors + Current BP:
• C-Statistic 0.727 [ 0.704 - 0.75 ]
Traditional risk factors + Current BP + Antecedent
BP (simple average):
• C-Statistic: 0.734 [ 0.711 - 0.756 ]
Traditional risk factors + Current BP + Antecedent
BP (weighted average):
• C-Statistic: 0.735 [ 0.712 - 0.757 ]
The C-Statistic is a standard measure of the predictive accuracy of a logistic regression
model; equivalent to the area under the receiver operating characteristic curve
The weighted average BP model had a slightly higher C-statistic than the simple
average BP model, indicating an improvement between models
Results: IDI & NRI Tests
• NRI (Categorical): considers movement between predefined ranges of risk
• NRI (Continuous): tests the incremental differences in predicted probabilities
• IDI: measures the new models’ improvement in average sensitivity without reduction in
average specificity
Current BP
vs.
Current BP + Simple Avg Ant BP
95% CI; P-value
Current BP + Simple Avg Ant BP
vs.
Current BP + Weighted Avg Ant BP
95% CI; P-value
NRI
(Categorical)
0.0143 [ 0.0058 - 0.0227 ]; 0.0001 -7e-04 [ -0.0044 - 0.003 ]; 0.705
NRI
(Continuous)
0.2366 [ 0.1447 - 0.3284 ]; 0 0.0902 [ -0.0023 - 0.1827 ]; 0.056
IDI 0.0072 [ 0.0029 - 0.0115 ]; 0.0011 7e-04 [ -5e-04 - 0.0019 ]; 0.260
*Test showed statistically significant improvements when
antecedent BP was added to the model; confirmed
previous studies’ findings
*Test showed a positive continuous NRI,
suggesting some improvement between models;
however, this value was not statistically significant
Weighted Antecedent BP= λ(E7) + λ(1-λ)(E6) + λ(1-λ)2 (E5) + λ(1-λ)3 (E4) + λ(1-λ)4 (E3) + λ(1-λ)5 (E2) + (1-λ)6 (E1)
λ = 0.31
1-Specifity
Sensitivity
Area = 0.830

More Related Content

What's hot

Aspirin for primary prevention in cad in type II DM
Aspirin for primary prevention in cad in type II DMAspirin for primary prevention in cad in type II DM
Aspirin for primary prevention in cad in type II DMPijush Kanti Mandal
 
Aspirin for primary prevention of CVD
Aspirin for primary prevention of CVDAspirin for primary prevention of CVD
Aspirin for primary prevention of CVDPinkesh Parmar
 
The Use of Aspirin for Primary Prevention of Cardiovascular Diseases - Dr. Mu...
The Use of Aspirin for Primary Prevention of Cardiovascular Diseases - Dr. Mu...The Use of Aspirin for Primary Prevention of Cardiovascular Diseases - Dr. Mu...
The Use of Aspirin for Primary Prevention of Cardiovascular Diseases - Dr. Mu...Mubashar A Choudry MD
 
Cards研究 糖尿病
Cards研究 糖尿病Cards研究 糖尿病
Cards研究 糖尿病celebox
 
Hypertension with comorbidity
Hypertension with comorbidityHypertension with comorbidity
Hypertension with comorbidityAadil Sayyed
 
Optimising hypertension management with the best drug combinations china to...
Optimising hypertension management with the best drug combinations   china to...Optimising hypertension management with the best drug combinations   china to...
Optimising hypertension management with the best drug combinations china to...SoM
 
2016 hope 3 cognitive outcomes slides
2016 hope 3 cognitive outcomes slides2016 hope 3 cognitive outcomes slides
2016 hope 3 cognitive outcomes slidesMarilyn Mann
 
Base Primary Prevention Decision Model
Base Primary Prevention Decision ModelBase Primary Prevention Decision Model
Base Primary Prevention Decision ModelCTSI at UCSF
 
Statins and diabetes
Statins and diabetesStatins and diabetes
Statins and diabetestgraphos
 
Moderate beer consumption may have positive effects on health
Moderate beer consumption may have positive effects on healthModerate beer consumption may have positive effects on health
Moderate beer consumption may have positive effects on healthPanimoliitto
 
Hope 3 trial acc 2016 (4) (1)
Hope 3 trial acc 2016 (4) (1)Hope 3 trial acc 2016 (4) (1)
Hope 3 trial acc 2016 (4) (1)Hirdesh Chawla
 
ACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & ResultsACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & Resultstheheart.org
 
Addressing hypertension to reduce the burden of stroke 19 feb2018 (1)
Addressing hypertension to reduce  the burden of stroke 19 feb2018 (1)Addressing hypertension to reduce  the burden of stroke 19 feb2018 (1)
Addressing hypertension to reduce the burden of stroke 19 feb2018 (1)Sudhir Kumar
 
Differences in clinical characteristics and its effect for outcomes
Differences in clinical characteristics and its effect for outcomesDifferences in clinical characteristics and its effect for outcomes
Differences in clinical characteristics and its effect for outcomesdrucsamal
 

What's hot (19)

Jc2
Jc2Jc2
Jc2
 
Aspirin for primary prevention in cad in type II DM
Aspirin for primary prevention in cad in type II DMAspirin for primary prevention in cad in type II DM
Aspirin for primary prevention in cad in type II DM
 
Osborn - Lipids 2019 cholesterol guidelines
Osborn - Lipids 2019 cholesterol guidelinesOsborn - Lipids 2019 cholesterol guidelines
Osborn - Lipids 2019 cholesterol guidelines
 
Aspirin for primary prevention of CVD
Aspirin for primary prevention of CVDAspirin for primary prevention of CVD
Aspirin for primary prevention of CVD
 
The Use of Aspirin for Primary Prevention of Cardiovascular Diseases - Dr. Mu...
The Use of Aspirin for Primary Prevention of Cardiovascular Diseases - Dr. Mu...The Use of Aspirin for Primary Prevention of Cardiovascular Diseases - Dr. Mu...
The Use of Aspirin for Primary Prevention of Cardiovascular Diseases - Dr. Mu...
 
Cards研究 糖尿病
Cards研究 糖尿病Cards研究 糖尿病
Cards研究 糖尿病
 
CV journal Club
CV journal ClubCV journal Club
CV journal Club
 
Hypertension with comorbidity
Hypertension with comorbidityHypertension with comorbidity
Hypertension with comorbidity
 
Optimising hypertension management with the best drug combinations china to...
Optimising hypertension management with the best drug combinations   china to...Optimising hypertension management with the best drug combinations   china to...
Optimising hypertension management with the best drug combinations china to...
 
2016 hope 3 cognitive outcomes slides
2016 hope 3 cognitive outcomes slides2016 hope 3 cognitive outcomes slides
2016 hope 3 cognitive outcomes slides
 
Base Primary Prevention Decision Model
Base Primary Prevention Decision ModelBase Primary Prevention Decision Model
Base Primary Prevention Decision Model
 
Statins and diabetes
Statins and diabetesStatins and diabetes
Statins and diabetes
 
Moderate beer consumption may have positive effects on health
Moderate beer consumption may have positive effects on healthModerate beer consumption may have positive effects on health
Moderate beer consumption may have positive effects on health
 
Hope 3 trial acc 2016 (4) (1)
Hope 3 trial acc 2016 (4) (1)Hope 3 trial acc 2016 (4) (1)
Hope 3 trial acc 2016 (4) (1)
 
Statins and diabetes risk
Statins and diabetes riskStatins and diabetes risk
Statins and diabetes risk
 
ACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & ResultsACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & Results
 
Addressing hypertension to reduce the burden of stroke 19 feb2018 (1)
Addressing hypertension to reduce  the burden of stroke 19 feb2018 (1)Addressing hypertension to reduce  the burden of stroke 19 feb2018 (1)
Addressing hypertension to reduce the burden of stroke 19 feb2018 (1)
 
Micro-albuminuria in non-diabetic, non-hypertensive cardiovascular disease (C...
Micro-albuminuria in non-diabetic, non-hypertensive cardiovascular disease (C...Micro-albuminuria in non-diabetic, non-hypertensive cardiovascular disease (C...
Micro-albuminuria in non-diabetic, non-hypertensive cardiovascular disease (C...
 
Differences in clinical characteristics and its effect for outcomes
Differences in clinical characteristics and its effect for outcomesDifferences in clinical characteristics and its effect for outcomes
Differences in clinical characteristics and its effect for outcomes
 

Similar to Ije Okafor_Poster

Is clinician gestalt undervalued in chest pain assessment in ED
Is clinician gestalt undervalued in chest pain assessment in EDIs clinician gestalt undervalued in chest pain assessment in ED
Is clinician gestalt undervalued in chest pain assessment in EDkellyam18
 
1120310-最新台灣高血壓治療指引.pdf
1120310-最新台灣高血壓治療指引.pdf1120310-最新台灣高血壓治療指引.pdf
1120310-最新台灣高血壓治療指引.pdfKs doctor
 
Million-Hearts-Initiative.pptx
Million-Hearts-Initiative.pptxMillion-Hearts-Initiative.pptx
Million-Hearts-Initiative.pptxderek462361
 
Why should we measure endothelial function
Why should we measure endothelial functionWhy should we measure endothelial function
Why should we measure endothelial functionEndothelix
 
Diabetic kidney disease
Diabetic kidney diseaseDiabetic kidney disease
Diabetic kidney diseaseJoel Topf
 
Statin Use Cancer Related Mortality M Wilmath Nov2012 Whh Adult Med
Statin Use Cancer Related Mortality M Wilmath Nov2012 Whh Adult MedStatin Use Cancer Related Mortality M Wilmath Nov2012 Whh Adult Med
Statin Use Cancer Related Mortality M Wilmath Nov2012 Whh Adult MedMario Wilmath
 
Evidence Based Approach to Pulmonary Thromboembolism
Evidence Based Approach to Pulmonary ThromboembolismEvidence Based Approach to Pulmonary Thromboembolism
Evidence Based Approach to Pulmonary ThromboembolismKristopher Maday
 
DIG (Digitalis Investigation Group)
DIG (Digitalis Investigation Group)DIG (Digitalis Investigation Group)
DIG (Digitalis Investigation Group)theheart.org
 
Cardiac risk ,lecture presented at Palermo,Italy 2009
Cardiac risk ,lecture presented at Palermo,Italy 2009Cardiac risk ,lecture presented at Palermo,Italy 2009
Cardiac risk ,lecture presented at Palermo,Italy 2009Claudio Melloni
 
Valut az rischio anest sia napoli dic 2008;italian + bibliografy
Valut az rischio anest sia napoli dic 2008;italian + bibliografyValut az rischio anest sia napoli dic 2008;italian + bibliografy
Valut az rischio anest sia napoli dic 2008;italian + bibliografyClaudio Melloni
 
8. #ifad2019 review of recent monitoring trials (edwards)
8. #ifad2019 review of recent monitoring trials (edwards)8. #ifad2019 review of recent monitoring trials (edwards)
8. #ifad2019 review of recent monitoring trials (edwards)International Fluid Academy
 
Coronary heart disease - epidemiology
Coronary heart disease - epidemiologyCoronary heart disease - epidemiology
Coronary heart disease - epidemiologyGarima Gupta
 
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...Sameer Shete
 
The Hypertension Guidelines JNC 8
The Hypertension Guidelines JNC 8 The Hypertension Guidelines JNC 8
The Hypertension Guidelines JNC 8 Utai Sukviwatsirikul
 
Copyright 2016 American Medical Association. All rights reserv.docx
Copyright 2016 American Medical Association. All rights reserv.docxCopyright 2016 American Medical Association. All rights reserv.docx
Copyright 2016 American Medical Association. All rights reserv.docxmelvinjrobinson2199
 
Copyright 2016 American Medical Association. All rights reserv.docx
Copyright 2016 American Medical Association. All rights reserv.docxCopyright 2016 American Medical Association. All rights reserv.docx
Copyright 2016 American Medical Association. All rights reserv.docxbobbywlane695641
 
John Gallacher - What next
John Gallacher - What nextJohn Gallacher - What next
John Gallacher - What nextangewatkins
 

Similar to Ije Okafor_Poster (20)

Is clinician gestalt undervalued in chest pain assessment in ED
Is clinician gestalt undervalued in chest pain assessment in EDIs clinician gestalt undervalued in chest pain assessment in ED
Is clinician gestalt undervalued in chest pain assessment in ED
 
1120310-最新台灣高血壓治療指引.pdf
1120310-最新台灣高血壓治療指引.pdf1120310-最新台灣高血壓治療指引.pdf
1120310-最新台灣高血壓治療指引.pdf
 
Million-Hearts-Initiative.pptx
Million-Hearts-Initiative.pptxMillion-Hearts-Initiative.pptx
Million-Hearts-Initiative.pptx
 
Why should we measure endothelial function
Why should we measure endothelial functionWhy should we measure endothelial function
Why should we measure endothelial function
 
Diabetic kidney disease
Diabetic kidney diseaseDiabetic kidney disease
Diabetic kidney disease
 
Statin Use Cancer Related Mortality M Wilmath Nov2012 Whh Adult Med
Statin Use Cancer Related Mortality M Wilmath Nov2012 Whh Adult MedStatin Use Cancer Related Mortality M Wilmath Nov2012 Whh Adult Med
Statin Use Cancer Related Mortality M Wilmath Nov2012 Whh Adult Med
 
Evidence Based Approach to Pulmonary Thromboembolism
Evidence Based Approach to Pulmonary ThromboembolismEvidence Based Approach to Pulmonary Thromboembolism
Evidence Based Approach to Pulmonary Thromboembolism
 
GUIAS AMERICANAS DE HIPERTENSION ARTERIAL 2017
GUIAS AMERICANAS DE HIPERTENSION ARTERIAL 2017GUIAS AMERICANAS DE HIPERTENSION ARTERIAL 2017
GUIAS AMERICANAS DE HIPERTENSION ARTERIAL 2017
 
DIG (Digitalis Investigation Group)
DIG (Digitalis Investigation Group)DIG (Digitalis Investigation Group)
DIG (Digitalis Investigation Group)
 
Cardiac risk ,lecture presented at Palermo,Italy 2009
Cardiac risk ,lecture presented at Palermo,Italy 2009Cardiac risk ,lecture presented at Palermo,Italy 2009
Cardiac risk ,lecture presented at Palermo,Italy 2009
 
Valut az rischio anest sia napoli dic 2008;italian + bibliografy
Valut az rischio anest sia napoli dic 2008;italian + bibliografyValut az rischio anest sia napoli dic 2008;italian + bibliografy
Valut az rischio anest sia napoli dic 2008;italian + bibliografy
 
8. #ifad2019 review of recent monitoring trials (edwards)
8. #ifad2019 review of recent monitoring trials (edwards)8. #ifad2019 review of recent monitoring trials (edwards)
8. #ifad2019 review of recent monitoring trials (edwards)
 
Sprint 2015 nejm
Sprint 2015 nejmSprint 2015 nejm
Sprint 2015 nejm
 
Symplicity htn3 acc14
Symplicity htn3 acc14Symplicity htn3 acc14
Symplicity htn3 acc14
 
Coronary heart disease - epidemiology
Coronary heart disease - epidemiologyCoronary heart disease - epidemiology
Coronary heart disease - epidemiology
 
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
DRUG PROFILE IN MYOCARDIAL INFARCTION WITH MONITORING OF POSTLYSIS COMPLICATI...
 
The Hypertension Guidelines JNC 8
The Hypertension Guidelines JNC 8 The Hypertension Guidelines JNC 8
The Hypertension Guidelines JNC 8
 
Copyright 2016 American Medical Association. All rights reserv.docx
Copyright 2016 American Medical Association. All rights reserv.docxCopyright 2016 American Medical Association. All rights reserv.docx
Copyright 2016 American Medical Association. All rights reserv.docx
 
Copyright 2016 American Medical Association. All rights reserv.docx
Copyright 2016 American Medical Association. All rights reserv.docxCopyright 2016 American Medical Association. All rights reserv.docx
Copyright 2016 American Medical Association. All rights reserv.docx
 
John Gallacher - What next
John Gallacher - What nextJohn Gallacher - What next
John Gallacher - What next
 

Ije Okafor_Poster

  • 1. Weighted Average Blood Pressure as a Predictor of Cardiovascular Disease Ije Okafor, Anthony Bonifonte M.S., Dr. Turgay Ayer PhD H . Milton Stewart School of Industrial & Systems Engineering, Georgia Institute of Technology, Atlanta, GA • Cardiovascular disease (CVD) is America’s leading health problem, and the leading cause of death worldwide • High blood pressure, also known as hypertension, is the most important risk factor for premature cardiovascular disease • Traditional risk factors for CVD include age, sex, cholesterol, smoking, diabetes, and elevated levels of BP Background: Previous Study: Conclusions: • Antecedent BP is a statistically significant predictor of CVD risk • Antecedent BP is a stronger predictor of CVD risk than current BP Study used the simple average of antecedent BP measurements Research Objective: Study Inclusion: Determine if weighted average antecedent BP is a better predictor of CVD risk than simple average antecedent BP • Framingham Heart Study • 3909 patients attended Baseline Exam 8 • 2127 patients met selection criteria Core logistic regression models: • Traditional risk factors + Current BP • Traditional risk factors + Antecedent BP • Traditional risk factors + Antecedent BP + Current BP Clinical Measurements: Current BP Model HR (95% CI) & P Value Antecedent BP Model HR (95% CI) & P Value Current and Antecedent BP Model HR (95% CI) & P Value Age 1.03 (1.02-1.04) <.001 1.03 (1.02-1.04) <.001 1.03 (1.02-1.04) <.001 Sex 1.75 (1.50-2.06) <.001 1.80 (1.52-2.10) <.001 1.79 (1.52-2.10) <.001 Smoking (yes/no) 1.31 (1.12-1.54) <.001 1.36 (1.16-1.60) <.001 1.35 (1.15-1.58) <.001 Diabetes (yes/no) 1.23 (1.04-1.47) .0186 1.24 (1.05-1.48) .0143 1.23 (1.03-1.47) .0195 Cholesterol (10 mg/dL) 1.03 (1.01-1.05) .0019 1.03 (1.00-1.01) .0028 1.03 (1.01-1.05) .0033 Diuretics 1.80 (1.35-2.40) <.001 1.46 (1.11-2.02) .0117 1.54 (1.14-2.07) .0043 Current BP (10 mm Hg) 1.23 (1.19-1.27) <.001 1.12 (1.06-1.18) <.001 Antecedent BP (10 mm Hg) 1.28 (1.24-1.36) <.001 1.16 (1.09-1.24) <.001 Methodology: Exponential Smoothing Assigns exponentially decreasing weights to older observations. Standard Formula: Ft+1 = (λ)Dt + (1-λ) Ft • Ft+1 = Final weighted observation • Dt = Current observation • Ft = Previous observation • λ = A weighing factor referred to as the smoothing constant 0.70048 0.7005 0.70052 0.70054 0.70056 0.70058 0.7006 0.70062 0.28 0.285 0.29 0.295 0.3 0.305 0.31 0.315 0.32 C-Index Smoothing Constant (λ ) Optimal Smoothing Constant Results: Weighted Average Model vs. Simple Average Model Current BP + Weighted Antecedent BP HR (95% CI) & P Value Current and Antecedent BP Model HR (95% CI) & P Value Age 1.03 (1.02-1.04) <.001 1.03 (1.02-1.04) <.001 Sex 1.78 (1.51-2.09) <.001 1.79 (1.52-2.10) <.001 Smoking (y/n) 1.35 (1.15-1.58) <.001 1.35 (1.15-1.58) <.001 Diabetes (y/n) 1.23 (1.03-1.46) .0217 1.23 (1.03-1.47) .0195 Cholesterol (mg/dL) 1.03 (1.01-1.05) .0039 1.03 (1.01-1.05) .0033 Diuretics 1.53 (1.14-2.05) .0051 1.54 (1.14-2.07) .0043 Current BP 1.11 (1.05-1.17) <.001 1.12 (1.06-1.18) <.001 Antecedent BP (Simple Avg) 1.16 (1.09-1.24) <.001 Antecedent BP (Weighted Avg) 1.17 (1.09-1.25) <.001 Conclusion: • Using a weighted antecedent BP average over a simple average showed some improvements; however, this data was not statistically significant • Refinement to this study may bring statistically significant results Study Limitations: • Predominately white study population • Older population; more cases of CVD • Sensitive smoothing constant Future Work: • Conduct a similar study on a more diverse population • Explore all possible smoothing constant values; apply to additional models • Explore weighing options outside of exponential smoothing Acknowledgements: References: 1. Bonifonte, Anthony, MS, Turgay Ayer, PhD, Emir Veledar, PhD, Allison Clark, BA, and Peter W.F. Wilson, MD. "Antecedent Blood Pressure as a Predictor of Cardiovascular Disease." Journal of American Society of Hypertension (2015): 690-96. Web. 1. Vasan, Ramachandran S., Joseph M. Massaro, Peter W.F. Wilson, Sudha Seshadri, Philip A. Wolf, Daniel Levy, and Ralph B. D'Agostino. "Antecedent Blood Pressure and Risk of Cardiovascular Disease: The Framingham Heart Study." Journal of the American Heart Association(2001): 48-53. Web 2. Chen, Ruijun, Kumar Dharmarajan, Vivek T. Kulkarni, Natdanai Punnanithinont, Aakriti Gupta, Behnood Bikdeli, Purav S. Mody, and Isuru Ranasinghe. "Most Important Outcomes Research Papers on Hypertension." Journal of the American Heart Association (2013): 26-35. Web. • Anthony Bonifonte, Graduate Advisor • Dr. Turgay Ayer, Faculty Advisor • SURE Program, Summer 2016 Results: C-Statistic Traditional risk factors + Current BP: • C-Statistic 0.727 [ 0.704 - 0.75 ] Traditional risk factors + Current BP + Antecedent BP (simple average): • C-Statistic: 0.734 [ 0.711 - 0.756 ] Traditional risk factors + Current BP + Antecedent BP (weighted average): • C-Statistic: 0.735 [ 0.712 - 0.757 ] The C-Statistic is a standard measure of the predictive accuracy of a logistic regression model; equivalent to the area under the receiver operating characteristic curve The weighted average BP model had a slightly higher C-statistic than the simple average BP model, indicating an improvement between models Results: IDI & NRI Tests • NRI (Categorical): considers movement between predefined ranges of risk • NRI (Continuous): tests the incremental differences in predicted probabilities • IDI: measures the new models’ improvement in average sensitivity without reduction in average specificity Current BP vs. Current BP + Simple Avg Ant BP 95% CI; P-value Current BP + Simple Avg Ant BP vs. Current BP + Weighted Avg Ant BP 95% CI; P-value NRI (Categorical) 0.0143 [ 0.0058 - 0.0227 ]; 0.0001 -7e-04 [ -0.0044 - 0.003 ]; 0.705 NRI (Continuous) 0.2366 [ 0.1447 - 0.3284 ]; 0 0.0902 [ -0.0023 - 0.1827 ]; 0.056 IDI 0.0072 [ 0.0029 - 0.0115 ]; 0.0011 7e-04 [ -5e-04 - 0.0019 ]; 0.260 *Test showed statistically significant improvements when antecedent BP was added to the model; confirmed previous studies’ findings *Test showed a positive continuous NRI, suggesting some improvement between models; however, this value was not statistically significant Weighted Antecedent BP= λ(E7) + λ(1-λ)(E6) + λ(1-λ)2 (E5) + λ(1-λ)3 (E4) + λ(1-λ)4 (E3) + λ(1-λ)5 (E2) + (1-λ)6 (E1) λ = 0.31 1-Specifity Sensitivity Area = 0.830